Matt O'Brien
Stock Analyst at Piper Sandler
(2.20)
# 2,826
Out of 4,974 analysts
185
Total ratings
42.86%
Success rate
-5.29%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SI Shoulder Innovations | Initiates: Overweight | $18 | $15.46 | +16.43% | 1 | Aug 25, 2025 | |
| CARL Carlsmed | Initiates: Overweight | $18 | $13.14 | +36.99% | 1 | Aug 18, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $80 → $55 | $39.32 | +39.88% | 4 | Aug 7, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $30 → $14 | $12.63 | +10.85% | 9 | Aug 7, 2025 | |
| DXCM DexCom | Maintains: Overweight | $90 → $100 | $80.49 | +24.24% | 12 | Jul 31, 2025 | |
| CNMD CONMED | Maintains: Overweight | $80 → $68 | $54.69 | +24.34% | 13 | Jul 31, 2025 | |
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $105.35 | +37.63% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $60.29 | +32.69% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $7.70 | +55.84% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $20.66 | +45.21% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 → $15 | $16.55 | -9.37% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $93.00 | +77.42% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $16.51 | +63.54% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $2 | $1.61 | +24.22% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.70 | -5.41% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $129.09 | +8.45% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $20.00 | +30.00% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $345.97 | -10.40% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $279.72 | +17.98% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $35.70 | +40.06% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $27.90 | -42.65% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $107.59 | +6.89% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $4.39 | +173.35% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $394.34 | +6.51% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $106.60 | +31.33% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $93.02 | -3.25% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $16.31 | +53.28% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.46 | +105.48% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $2.05 | +119.51% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $105.03 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.71 | +453.51% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $68.68 | +58.34% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $1.49 | +1,120.13% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $23.87 | +235.15% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.10 | +192.68% | 1 | Jun 24, 2020 |
Shoulder Innovations
Aug 25, 2025
Initiates: Overweight
Price Target: $18
Current: $15.46
Upside: +16.43%
Carlsmed
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.14
Upside: +36.99%
PROCEPT BioRobotics
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $55
Current: $39.32
Upside: +39.88%
Tandem Diabetes Care
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $12.63
Upside: +10.85%
DexCom
Jul 31, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $80.49
Upside: +24.24%
CONMED
Jul 31, 2025
Maintains: Overweight
Price Target: $80 → $68
Current: $54.69
Upside: +24.34%
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $105.35
Upside: +37.63%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $60.29
Upside: +32.69%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $7.70
Upside: +55.84%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $20.66
Upside: +45.21%
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $16.55
Upside: -9.37%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $93.00
Upside: +77.42%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $16.51
Upside: +63.54%
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.61
Upside: +24.22%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.70
Upside: -5.41%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $129.09
Upside: +8.45%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $20.00
Upside: +30.00%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $345.97
Upside: -10.40%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $279.72
Upside: +17.98%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $35.70
Upside: +40.06%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $27.90
Upside: -42.65%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $107.59
Upside: +6.89%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $4.39
Upside: +173.35%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $394.34
Upside: +6.51%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $106.60
Upside: +31.33%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $93.02
Upside: -3.25%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $16.31
Upside: +53.28%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.46
Upside: +105.48%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $2.05
Upside: +119.51%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $105.03
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.71
Upside: +453.51%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $68.68
Upside: +58.34%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $1.49
Upside: +1,120.13%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $23.87
Upside: +235.15%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.10
Upside: +192.68%